These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33739790)

  • 21. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
    Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
    Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
    Li CJ; Lin LT; Hou MF; Chu PY
    Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 and MHC Class I Expression in High-grade Ovarian Cancers, Including Platinum-resistant Recurrences Treated With Checkpoint Inhibitor Therapy.
    Griesinger L; Nyarko-Odoom A; Martinez SA; Shen NW; Ring KL; Gaughan EM; Mills AM
    Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):197-203. PubMed ID: 36812389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.
    Santoni M; Romagnoli E; Saladino T; Foghini L; Guarino S; Capponi M; Giannini M; Cognigni PD; Ferrara G; Battelli N
    Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):78-84. PubMed ID: 29126881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
    Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA
    Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
    Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
    BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy.
    Roberts JA; Gonzalez RS; Das S; Berlin J; Shi C
    Hum Pathol; 2017 Dec; 70():49-54. PubMed ID: 29037958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune checkpoints in aggressive breast cancer subtypes.
    Zawlik I; Gablo N; Szymanska B; Pawlowska Z; Chudobinski C; Chalubinska-Fendler J; Morawiec Z; Zielinska-Blizniewska H; Morawiec-Sztandera A; Kolacinska A
    Neoplasma; 2016; 63(5):768-73. PubMed ID: 27468881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
    Wang X; Liu Y
    Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay.
    Cimadamore A; Massari F; Santoni M; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R; Moch H
    Curr Drug Targets; 2020; 21(16):1664-1671. PubMed ID: 32208115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
    Özcan D; Lade-Keller J; Tramm T
    Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma.
    Salisbury T; Abozina A; Zhang C; Mao E; Banyi N; Leo J; Ionescu D; Zhou C; Wang G
    Ann Diagn Pathol; 2022 Apr; 57():151901. PubMed ID: 35091156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.
    Wu J; Wang W; Gao L; Shao X; Wang X
    Cancer; 2024 Apr; 130(S8):1449-1463. PubMed ID: 38482921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
    Šmahel M
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor Mutational Burden and
    Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
    Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of PD-L1 using SP142 CDx in triple negative breast cancer.
    Al-Jussani GN; Dabbagh TZ; Al-Rimawi D; Sughayer MA
    Ann Diagn Pathol; 2021 Apr; 51():151703. PubMed ID: 33454500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes.
    Sanuki F; Mikami Y; Nishimura H; Fujita Y; Monobe Y; Nomura T; Taira N; Moriya T
    Breast Cancer; 2023 Nov; 30(6):1041-1053. PubMed ID: 37642903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.